

Neostigmine

Essential medicine status

General description

Neostigmine is a reversible anticholinesterase agent indicated as a treatment for myasthenia gravis; and for use in the reversal of non-depolarizing muscle relaxants administered during surgery.

INN

Neostigmine bromide

ATC codes

[N07AA01](#)

Medicine type

Chemical agent

EML status history

First added in 1977 ([TRS 615](#)) for [Anticholinesterase reversible](#)

Added in 1977 ([TRS 615](#)) for [Myasthenia gravis](#)

Added in 2025 ([TRS 1064](#)) for [Myasthenia gravis](#)

Wikipedia

[Neostigmine](#)

DrugBank

[Neostigmine](#)

Recommendations

Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

- Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)
- Oral > Solid > tablet: 15 mg (neostigmine bromide)

Indications

[Anticholinesterase reversible Myasthenia gravis](#)

Section

Medicines for myasthenia gravis

- Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)
- Oral > Solid > tablet: 15 mg (neostigmine bromide)

Indications

[Myasthenia gravis](#)